Skip to Content

Tretten Approval History

FDA Approved: Yes (First approved December 23, 2013)
Brand name: Tretten
Generic name: coagulation factor XIII A-subunit (recombinant)
Company: Novo Nordisk
Treatment for: Factor XIII A-Subunit Deficiency

Tretten (coagulation factor XIII A-subunit (recombinant)) is a recombinant analogue of the human Factor XIII A-subunit for the prevention of bleeding in patients who have the rare clotting disorder congenital Factor XIII A-subunit deficiency.

Development History and FDA Approval Process for Tretten

DateArticle
Dec 23, 2013Approval FDA Approves Tretten to Treat Rare Genetic Clotting Disorder

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide